Recently, Mundy et al1 indicated that some statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG Co-A] reductase inhibitors) have a potent stimulatory effect on bone formation in vitro and in experimental animals. However, Wada et al2 found that bone mineral density (BMD) did not increase, but rather unexpectedly decreased in subjects with type 2 diabetes mellitus who are receiving therapy with statins compared with those who are not.
Koshiyama H, Wada Y, Nakamura Y. Hypercholesterolemia as a Possible Risk Factor for Osteopenia in Type 2 Diabetes Mellitus. Arch Intern Med. 2001;161(13):1678. doi: